About Morphotek
Morphotek is a company based in Exton (United States) founded in 2000 was acquired by Eisai in March 2007.. Morphotek has raised $79.5 million across 18 funding rounds from investors including Eisai, dsm-firmenich and HHS. Morphotek operates in a competitive market with competitors including Moderna, BeiGene, Aclaris Therapeutics, Incyte and Ultragenyx, among others.
- Headquarter Exton, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Morphotek
Morphotek has successfully raised a total of $79.5M across 18 strategic funding rounds. The most recent funding activity was a Grant round of $947 thousand completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 18
- Last Round Grant — $947,000
-
First Round
First Round
(22 May 2000)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2011 | Amount | Grant - Morphotek | Valuation |
investors |
|
| Feb, 2011 | Amount | Grant - Morphotek | Valuation |
investors |
|
| Sep, 2009 | Amount | Grant - Morphotek | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Morphotek
Morphotek has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Eisai, dsm-firmenich and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors
|
Founded Year | Domain | Location | |
|
Investments are directed toward young firms in pharmaceuticals and biotech.
|
Founded Year | Domain | Location | |
|
Life Sciences focused VC firm that does early stage investments in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Morphotek
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Morphotek
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Morphotek Comparisons
Competitors of Morphotek
Morphotek operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Aclaris Therapeutics, Incyte and Ultragenyx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Morphotek
Frequently Asked Questions about Morphotek
When was Morphotek founded?
Morphotek was founded in 2000.
Where is Morphotek located?
Morphotek is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.
Is Morphotek a funded company?
Morphotek is a funded company, having raised a total of $79.5M across 18 funding rounds to date. The company's 1st funding round was a Grant of $843.29K, raised on May 22, 2000.
What does Morphotek do?
Morphotek develops biological-based products to treat cancer, inflammation, and infectious diseases. Has several monoclonal antibodies (mAbs) in clinical development for cancer and inflammatory disease. Its lead program, farletuzumab is for patients with platinum-sensitive, relapsed ovarian cancer (received orphan drug designation) and 1st line non-small cell lung cancer. Its other lead antibody monoclonal programs, amatuximab, and ontuxizumab. Amatuximab, ontuxizumab has received orphan drug designation for malignant pleural mesothelioma and for sarcoma respectively. Its other investigational mAbs programs are against inflammatory and infectious diseases.
Who are the top competitors of Morphotek?
Morphotek's top competitors include Moderna, BeiGene and Escient Pharmaceuticals.
Who are Morphotek's investors?
Morphotek has 16 investors. Key investors include Eisai, dsm-firmenich, HHS, Flagship Pioneering, and DARPA.